Details
| Stereochemistry | ABSOLUTE |
| Molecular Formula | C23H26FN5O3 |
| Molecular Weight | 439.4826 |
| Optical Activity | UNSPECIFIED |
| Defined Stereocenters | 1 / 1 |
| E/Z Centers | 1 |
| Charge | 0 |
SHOW SMILES / InChI
SMILES
CN(C)C(=O)N1CC[C@@H](C1)NC(=O)C2=C(C)NC(\C=C3/C(=O)NC4=C3C=C(F)C=C4)=C2C
InChI
InChIKey=KMIOJWCYOHBUJS-HAKPAVFJSA-N
InChI=1S/C23H26FN5O3/c1-12-19(10-17-16-9-14(24)5-6-18(16)27-21(17)30)25-13(2)20(12)22(31)26-15-7-8-29(11-15)23(32)28(3)4/h5-6,9-10,15,25H,7-8,11H2,1-4H3,(H,26,31)(H,27,30)/b17-10-/t15-/m0/s1
| Molecular Formula | C23H26FN5O3 |
| Molecular Weight | 439.4826 |
| Charge | 0 |
| Count |
|
| Stereochemistry | ABSOLUTE |
| Additional Stereochemistry | No |
| Defined Stereocenters | 1 / 1 |
| E/Z Centers | 1 |
| Optical Activity | UNSPECIFIED |
Approval Year
Cmax
| Value | Dose | Co-administered | Analyte | Population |
|---|---|---|---|---|
118 ng/mL EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/30478190/ |
50 mg 1 times / day multiple, oral dose: 50 mg route of administration: Oral experiment type: MULTIPLE co-administered: |
VOROLANIB plasma | Homo sapiens population: UNHEALTHY age: ADULT sex: FEMALE / MALE food status: FASTED |
|
315 ng/mL EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/30478190/ |
100 mg 1 times / day multiple, oral dose: 100 mg route of administration: Oral experiment type: MULTIPLE co-administered: |
VOROLANIB plasma | Homo sapiens population: UNHEALTHY age: ADULT sex: FEMALE / MALE food status: FASTED |
|
346 ng/mL EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/30478190/ |
150 mg 1 times / day multiple, oral dose: 150 mg route of administration: Oral experiment type: MULTIPLE co-administered: |
VOROLANIB plasma | Homo sapiens population: UNHEALTHY age: ADULT sex: FEMALE / MALE food status: FASTED |
|
560 ng/mL EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/30478190/ |
150 mg 1 times / day multiple, oral dose: 150 mg route of administration: Oral experiment type: MULTIPLE co-administered: |
VOROLANIB plasma | Homo sapiens population: UNHEALTHY age: ADULT sex: FEMALE / MALE food status: FED |
|
446 ng/mL EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/30478190/ |
200 mg 1 times / day multiple, oral dose: 200 mg route of administration: Oral experiment type: MULTIPLE co-administered: |
VOROLANIB plasma | Homo sapiens population: UNHEALTHY age: ADULT sex: FEMALE / MALE food status: FED |
|
646 ng/mL EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/30478190/ |
300 mg 1 times / day multiple, oral dose: 300 mg route of administration: Oral experiment type: MULTIPLE co-administered: |
VOROLANIB plasma | Homo sapiens population: UNHEALTHY age: ADULT sex: FEMALE / MALE food status: FED |
|
804 ng/mL EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/30478190/ |
400 mg 1 times / day multiple, oral dose: 400 mg route of administration: Oral experiment type: MULTIPLE co-administered: |
VOROLANIB plasma | Homo sapiens population: UNHEALTHY age: ADULT sex: FEMALE / MALE food status: FED |
|
936 ng/mL EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/30478190/ |
600 mg 1 times / day multiple, oral dose: 600 mg route of administration: Oral experiment type: MULTIPLE co-administered: |
VOROLANIB plasma | Homo sapiens population: UNHEALTHY age: ADULT sex: FEMALE / MALE food status: FED |
|
727 ng/mL EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/30478190/ |
800 mg 1 times / day multiple, oral dose: 800 mg route of administration: Oral experiment type: MULTIPLE co-administered: |
VOROLANIB plasma | Homo sapiens population: UNHEALTHY age: ADULT sex: FEMALE / MALE food status: FED |
AUC
| Value | Dose | Co-administered | Analyte | Population |
|---|---|---|---|---|
1300 ng × h/mL EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/30478190/ |
50 mg 1 times / day multiple, oral dose: 50 mg route of administration: Oral experiment type: MULTIPLE co-administered: |
VOROLANIB plasma | Homo sapiens population: UNHEALTHY age: ADULT sex: FEMALE / MALE food status: FASTED |
|
2940 ng × h/mL EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/30478190/ |
100 mg 1 times / day multiple, oral dose: 100 mg route of administration: Oral experiment type: MULTIPLE co-administered: |
VOROLANIB plasma | Homo sapiens population: UNHEALTHY age: ADULT sex: FEMALE / MALE food status: FASTED |
|
3360 ng × h/mL EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/30478190/ |
150 mg 1 times / day multiple, oral dose: 150 mg route of administration: Oral experiment type: MULTIPLE co-administered: |
VOROLANIB plasma | Homo sapiens population: UNHEALTHY age: ADULT sex: FEMALE / MALE food status: FASTED |
|
6410 ng × h/mL EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/30478190/ |
150 mg 1 times / day multiple, oral dose: 150 mg route of administration: Oral experiment type: MULTIPLE co-administered: |
VOROLANIB plasma | Homo sapiens population: UNHEALTHY age: ADULT sex: FEMALE / MALE food status: FED |
|
4360 ng × h/mL EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/30478190/ |
200 mg 1 times / day multiple, oral dose: 200 mg route of administration: Oral experiment type: MULTIPLE co-administered: |
VOROLANIB plasma | Homo sapiens population: UNHEALTHY age: ADULT sex: FEMALE / MALE food status: FED |
|
5870 ng × h/mL EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/30478190/ |
300 mg 1 times / day multiple, oral dose: 300 mg route of administration: Oral experiment type: MULTIPLE co-administered: |
VOROLANIB plasma | Homo sapiens population: UNHEALTHY age: ADULT sex: FEMALE / MALE food status: FED |
|
10200 ng × h/mL EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/30478190/ |
400 mg 1 times / day multiple, oral dose: 400 mg route of administration: Oral experiment type: MULTIPLE co-administered: |
VOROLANIB plasma | Homo sapiens population: UNHEALTHY age: ADULT sex: FEMALE / MALE food status: FED |
|
8270 ng × h/mL EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/30478190/ |
600 mg 1 times / day multiple, oral dose: 600 mg route of administration: Oral experiment type: MULTIPLE co-administered: |
VOROLANIB plasma | Homo sapiens population: UNHEALTHY age: ADULT sex: FEMALE / MALE food status: FED |
|
5950 ng × h/mL EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/30478190/ |
800 mg 1 times / day multiple, oral dose: 800 mg route of administration: Oral experiment type: MULTIPLE co-administered: |
VOROLANIB plasma | Homo sapiens population: UNHEALTHY age: ADULT sex: FEMALE / MALE food status: FED |
T1/2
| Value | Dose | Co-administered | Analyte | Population |
|---|---|---|---|---|
8.4 h EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/30478190/ |
50 mg 1 times / day multiple, oral dose: 50 mg route of administration: Oral experiment type: MULTIPLE co-administered: |
VOROLANIB plasma | Homo sapiens population: UNHEALTHY age: ADULT sex: FEMALE / MALE food status: FASTED |
|
7.3 h EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/30478190/ |
100 mg 1 times / day multiple, oral dose: 100 mg route of administration: Oral experiment type: MULTIPLE co-administered: |
VOROLANIB plasma | Homo sapiens population: UNHEALTHY age: ADULT sex: FEMALE / MALE food status: FASTED |
|
8.5 h EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/30478190/ |
150 mg 1 times / day multiple, oral dose: 150 mg route of administration: Oral experiment type: MULTIPLE co-administered: |
VOROLANIB plasma | Homo sapiens population: UNHEALTHY age: ADULT sex: FEMALE / MALE food status: FASTED |
|
5 h EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/30478190/ |
150 mg 1 times / day multiple, oral dose: 150 mg route of administration: Oral experiment type: MULTIPLE co-administered: |
VOROLANIB plasma | Homo sapiens population: UNHEALTHY age: ADULT sex: FEMALE / MALE food status: FED |
|
5.8 h EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/30478190/ |
200 mg 1 times / day multiple, oral dose: 200 mg route of administration: Oral experiment type: MULTIPLE co-administered: |
VOROLANIB plasma | Homo sapiens population: UNHEALTHY age: ADULT sex: FEMALE / MALE food status: FED |
|
7.8 h EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/30478190/ |
300 mg 1 times / day multiple, oral dose: 300 mg route of administration: Oral experiment type: MULTIPLE co-administered: |
VOROLANIB plasma | Homo sapiens population: UNHEALTHY age: ADULT sex: FEMALE / MALE food status: FED |
|
6 h EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/30478190/ |
400 mg 1 times / day multiple, oral dose: 400 mg route of administration: Oral experiment type: MULTIPLE co-administered: |
VOROLANIB plasma | Homo sapiens population: UNHEALTHY age: ADULT sex: FEMALE / MALE food status: FED |
|
5.6 h EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/30478190/ |
600 mg 1 times / day multiple, oral dose: 600 mg route of administration: Oral experiment type: MULTIPLE co-administered: |
VOROLANIB plasma | Homo sapiens population: UNHEALTHY age: ADULT sex: FEMALE / MALE food status: FED |
|
4.2 h EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/30478190/ |
800 mg 1 times / day multiple, oral dose: 800 mg route of administration: Oral experiment type: MULTIPLE co-administered: |
VOROLANIB plasma | Homo sapiens population: UNHEALTHY age: ADULT sex: FEMALE / MALE food status: FED |
| Substance Class |
Chemical
Created
by
admin
on
Edited
Mon Mar 31 21:31:31 GMT 2025
by
admin
on
Mon Mar 31 21:31:31 GMT 2025
|
| Record UNII |
YP8G3I74EL
|
| Record Status |
Validated (UNII)
|
| Record Version |
|
-
Download
| Name | Type | Language | ||
|---|---|---|---|---|
|
Official Name | English | ||
|
Preferred Name | English | ||
|
Systematic Name | English | ||
|
Common Name | English |
| Classification Tree | Code System | Code | ||
|---|---|---|---|---|
|
NCI_THESAURUS |
C129825
Created by
admin on Mon Mar 31 21:31:31 GMT 2025 , Edited by admin on Mon Mar 31 21:31:31 GMT 2025
|
||
|
NCI_THESAURUS |
C93259
Created by
admin on Mon Mar 31 21:31:31 GMT 2025 , Edited by admin on Mon Mar 31 21:31:31 GMT 2025
|
| Code System | Code | Type | Description | ||
|---|---|---|---|---|---|
|
CHEMBL3545401
Created by
admin on Mon Mar 31 21:31:31 GMT 2025 , Edited by admin on Mon Mar 31 21:31:31 GMT 2025
|
PRIMARY | |||
|
10338
Created by
admin on Mon Mar 31 21:31:31 GMT 2025 , Edited by admin on Mon Mar 31 21:31:31 GMT 2025
|
PRIMARY | |||
|
C95896
Created by
admin on Mon Mar 31 21:31:31 GMT 2025 , Edited by admin on Mon Mar 31 21:31:31 GMT 2025
|
PRIMARY | |||
|
59215954
Created by
admin on Mon Mar 31 21:31:31 GMT 2025 , Edited by admin on Mon Mar 31 21:31:31 GMT 2025
|
PRIMARY | |||
|
1013920-15-4
Created by
admin on Mon Mar 31 21:31:31 GMT 2025 , Edited by admin on Mon Mar 31 21:31:31 GMT 2025
|
PRIMARY | |||
|
CHEMBL3545427
Created by
admin on Mon Mar 31 21:31:31 GMT 2025 , Edited by admin on Mon Mar 31 21:31:31 GMT 2025
|
PRIMARY | |||
|
DB15247
Created by
admin on Mon Mar 31 21:31:31 GMT 2025 , Edited by admin on Mon Mar 31 21:31:31 GMT 2025
|
PRIMARY | |||
|
YP8G3I74EL
Created by
admin on Mon Mar 31 21:31:31 GMT 2025 , Edited by admin on Mon Mar 31 21:31:31 GMT 2025
|
PRIMARY | |||
|
100000174662
Created by
admin on Mon Mar 31 21:31:31 GMT 2025 , Edited by admin on Mon Mar 31 21:31:31 GMT 2025
|
PRIMARY |
| Related Record | Type | Details | ||
|---|---|---|---|---|
|
TARGET -> INHIBITOR | |||
|
TARGET -> INHIBITOR | |||
|
TARGET -> INHIBITOR | |||
|
TARGET -> INHIBITOR |
| Related Record | Type | Details | ||
|---|---|---|---|---|
|
|
ACTIVE MOIETY |
